{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:00:20Z","timestamp":1791306020702,"version":"4.3.1"},"reference-count":37,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.2711","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T01:39:12Z","timestamp":1410831552000},"page":"2159-2163","source":"Crossref","is-referenced-by-count":6,"title":["Successful Treatment of Persistent MRSA Bacteremia using High-dose Daptomycin Combined with Rifampicin"],"prefix":"10.2169","volume":"53","author":[{"given":"Hideharu","family":"Hagiya","sequence":"first","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terasaka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Satou","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kikuko","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Waseda","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Hanayama","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in <i>Staphylococcus aureus<\/i> Bacteremia. Clin Microbiol Rev 25: 362-386, 2012.","DOI":"10.1128\/CMR.05022-11"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lowy FD. <i>Staphylococcus aureus<\/i> infections. N Engl J Med 339: 520-532, 1998.","DOI":"10.1056\/NEJM199808203390806"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated <i>Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 40: 695-703, 2005.","DOI":"10.1086\/427806"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus<\/i>. Infect Control Hosp Epidemiol 28: 273-279, 2007.","DOI":"10.1086\/512627"},{"key":"5","unstructured":"5. Malani PN, Rana MM, Banerjee M, et al. <i>Staphylococcus aureus<\/i> bloodstream infections: the association between age and mortality and functional status. J Am Geriatr Soc 56: 1485-1489, 2008."},{"key":"6","unstructured":"6. Jensen AG, Wachmann CH, Espersen F, et al. Treatment and outcome of <i>Staphylococcus aureus<\/i> bacteremia: a prospective study of 278 cases. Arch Intern Med 162: 25-32, 2002."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wang JL, Chen SY, Wang JT, et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant <i>Staphylococcus aureus<\/i> and methicillin-susceptible <i>S. aureus<\/i>. Clin Infect Dis 46: 799-806, 2008.","DOI":"10.1086\/527389"},{"key":"8","unstructured":"8. Turnidge JD, Kotsanas D, Munckhof W, et al. <i>Staphylococcus aureus<\/i> bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 191: 368-373, 2009."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in <i>Staphylococcus aureus<\/i>. Antimicrob Agents Chemother 47: 2538-2544, 2003.","DOI":"10.1128\/AAC.47.8.2538-2544.2003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> infections in adults and children. Clin Infect Dis 52: e18-e55, 2011.","DOI":"10.1093\/cid\/ciq146"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically Ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 57: 1568-1576, 2013.","DOI":"10.1093\/cid\/cit582"},{"key":"12","unstructured":"12. Hawkins C, Huang J, Jin N, et al. Persistent <i>Staphylococcus aureus<\/i> bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 167: 1861-1867, 2007."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lin SH, Lai CC, Tan CK, et al. Comparative efficacy of vancomycin and teicoplanin in the treatment of hospitalised elderly patients with persistent meticillin-resistant <i>Staphylococcus aureus<\/i> (MRSA) bacteraemia. Int J Antimicrob Agents 37: 179-181, 2011.","DOI":"10.1016\/j.ijantimicag.2010.10.018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lin SH, Liao WH, Lai CC, et al. Risk factors for mortality in patients with persistent methicillin-resistant <i>Staphylococcus aureus<\/i> bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob Chemother 65: 1792-1798, 2010.","DOI":"10.1093\/jac\/dkq188"},{"key":"15","unstructured":"15. Khatib R, Johnson LB, Fakih MG, et al. Persistence in <i>Staphylococcus aureus<\/i> bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 38: 7-14, 2006."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Neuner EA, Casabar E, Reichley R, et al. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia. Diagn Microbiol Infect Dis 67: 228-233, 2010.","DOI":"10.1016\/j.diagmicrobio.2010.02.026"},{"key":"17","unstructured":"17. Conners CK, Epstein JN, March JS, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry 40: 159-167, 2001."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant <i>Staphylococcus aureus<\/i> with reduced vancomycin susceptibility. Clin Infect Dis 38: 521-528, 2004.","DOI":"10.1086\/381202"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate <i>Staphylococcus aureus<\/i>. Clin Infect Dis 38: 448-451, 2004.","DOI":"10.1086\/381093"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315-3320, 2008.","DOI":"10.1128\/AAC.00113-08"},{"key":"21","unstructured":"21. Wang JL, Wang JT, Sheng WH, et al. Nosocomial methicillin-resistant <i>Staphylococcus aureus<\/i> (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2 mg\/L, by the broth microdilution method. BMC Infect Dis 10: 159, 2010."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for <i>Staphylococcus aureus<\/i>. Clin Infect Dis 44: 1208-1215, 2007.","DOI":"10.1086\/513203"},{"key":"23","unstructured":"23. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in <i>Staphylococcus aureus<\/i> infections: a systematic review and meta-analysis. Clin Infect Dis 54: 755-771, 2012."},{"key":"24","unstructured":"24. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant <i>Staphylococcus aureus<\/i> infections: efficacy and toxicity. Arch Intern Med 166: 2138-2144, 2006."},{"key":"25","unstructured":"25. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia: trends over 11 years. J Clin Microbiol 47: 1640-1644, 2009."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia. Clin Infect Dis 46: 193-200, 2008.","DOI":"10.1086\/524667"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. van Hal SJ, Fowler VG Jr. Is it time to replace vancomycin in the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> infections? Clin Infect Dis 56: 1779-1788, 2013.","DOI":"10.1093\/cid\/cit178"},{"key":"28","unstructured":"28. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of <i>Staphylococcus aureus<\/i> bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 82: 322-332, 2003."},{"key":"29","unstructured":"29. Khatib R, Johnson LB, Sharma M, et al. Persistent <i>Staphylococcus aureus<\/i> bacteremia: incidence and outcome trends over time. Scand J Infect Dis 41: 4-9, 2009."},{"key":"30","unstructured":"30. Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant <i>Staphylococcus aureus<\/i>: a survey of infectious diseases consultants. Clin Infect Dis 43: e42-e45, 2006."},{"key":"31","unstructured":"31. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 49: 395-401, 2009."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant <i>Staphylococcus<\/i> bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51: 1656-1660, 2007.","DOI":"10.1128\/AAC.00350-06"},{"key":"33","unstructured":"33. Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant <i>Staphylococcus aureus<\/i> with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54: 51-58, 2012."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother 19: 732-739, 2013.","DOI":"10.1007\/s10156-013-0559-z"},{"key":"35","unstructured":"35. Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of <i>Staphylococcus aureus<\/i> infections: a systematic review of the literature. Arch Intern Med 168: 805-819, 2008."},{"key":"36","unstructured":"36. Hagelund CH, Wahlen P, Eidsaunet W. Absorption of rifampicin in gastrectomized patients. Effect of meals. Scand J Respir Dis 58: 241-246, 1977."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 12: 159-218, 1981.","DOI":"10.3109\/03602538109011084"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/18\/53_53.2711\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:52:42Z","timestamp":1621446762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/18\/53_53.2711\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":37,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.2711","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}